Anzeige
Erschienen in:
01.08.2014 | Erratum
Erratum to: Mortality of patients with multiple sclerosis: a cohort study in UK primary care
Erschienen in: Journal of Neurology | Ausgabe 8/2014
Einloggen, um Zugang zu erhaltenExcerpt
Unfortunately, the online published article has errors in footnote of Tables 1, 2 and 3. The correct tables are given in the following pages.
Table 1
Basic characteristics of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MS
|
Characteristic
|
MS cases
N = 1,822 [n (%)]
|
Referents
N = 18,211 [n (%)]
|
RRMSa
N = 769 [n (%)]
|
Referents
N = 7,690 [n (%)]
|
PPMS
N = 125 [n (%)]
|
Referents
N = 1,250 [n (%)]
|
|---|---|---|---|---|---|---|
|
Mean age (years) at cohort entry (index date; SD)
|
42.08 (11.79)
|
42.0 (11.72)
|
40.01 (11.14)
|
39.94 (11.15)
|
49.98 (10.43)
|
49.92 (10.39)
|
|
Sex
|
||||||
|
Males
|
481 (26.40)
|
4,801 (26.36)
|
193 (25.10)
|
1,930 (25.10)
|
53 (42.40)
|
530 (42.40)
|
|
Females
|
1,341 (73.60)
|
13,410 (73.64)
|
576 (74.90)
|
5,760 (74.90)
|
72 (57.60)
|
720 (57.60)
|
|
Smoking status
|
||||||
|
Current*,†
|
569 (31.23)
|
4,363 (23.96)
|
226 (29.39)
|
1,902 (24.73)
|
40 (32.00)
|
289 (23.12)
|
|
Former
|
239 (13.12)
|
2,390 (13.12)
|
101 (13.13)
|
963 (12.52)
|
23 (18.40)
|
199 (15.92)
|
|
Never
|
777 (42.65)
|
8,921 (48.99)
|
349 (45.38)
|
3,807 (49.51)
|
50 (40.00)
|
595 (47.60)
|
|
Unknown
|
237 (13.01)
|
2,537 (13.93)
|
93 (12.09)
|
1,018 (13.24)
|
12 (9.60)
|
167 (13.36)
|
|
BMI (kg/m2)
|
||||||
|
<18.5
|
46 (2.52)
|
379 (2.08)
|
17 (2.21)
|
179 (2.33)
|
2 (1.60)
|
18 (1.44)
|
|
18.5–24.99
|
706 (38.75)
|
6,948 (38.15)
|
301 (39.14)
|
2,980 (38.75)
|
46 (36.80)
|
408 (32.64)
|
|
25.0–29.99
|
426 (23.38)
|
4,100 (22.51)
|
187 (24.32)
|
1,676 (21.79)
|
39 (31.20)
|
339 (27.12)
|
|
≥30
|
248 (13.61)
|
2,406 (13.21)
|
112 (14.56)
|
993 (12.91)
|
12 (9.60)
|
198 (15.84)
|
|
Unknown
|
396 (21.73)
|
4,378 (24.04)
|
152 (19.77)
|
1,862 (24.21)
|
26 (20.80)
|
287 (22.96)
|
|
Alcohol abuse†
|
25 (1.37)
|
370 (2.03)
|
3 (0.39)
|
133 (1.73)
|
5 (4.0)
|
50 (4.0)
|
|
Mean length of recorded medical history (years; SD)
|
||||||
|
Before index date
|
7.86 (4.44)
|
7.97 (4.43)
|
7.93 (4.50)
|
8.03 (4.49)
|
8.83 (4.51)
|
9.02 (4.52)
|
|
Follow-up after index date†
|
7.85 (4.50)
|
7.95 (4.49)
|
8.95 (4.33)
|
8.18 (4.40)
|
8.15 (4.32)
|
8.15 (4.08)
|
Table 2
Comorbidities of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MS
|
Characteristic
|
MS cases
N = 1,822 [n (%)]
|
Referents
N = 18,211 [n (%)]
|
RRMSa cases
N = 769 [n (%)]
|
Referents
N = 7,690 [n (%)]
|
PPMS cases
N = 125 [n (%)]
|
Referents
N = 1,250 [n (%)]
|
|---|---|---|---|---|---|---|
|
Chronic comorbiditiesb
|
||||||
|
COPD and asthma
|
302 (16.58)
|
2,890 (15.87)
|
117 (15.21)
|
1,245 (16.19)
|
18 (14.40)
|
197 (15.76)
|
|
Depression*,†,§
|
508 (27.88)
|
3,677 (20.19)
|
188 (24.45)
|
1,529 (19.88)
|
45 (36.00)
|
238 (19.04)
|
|
Diabetes
|
35 (1.92)
|
390 (2.14)
|
13 (1.69)
|
141 (1.83)
|
3 (2.40)
|
44 (3.52)
|
|
Hypertension
|
137 (7.52)
|
1,544 (8.48)
|
47 (6.11)
|
538 (7.00)
|
13 (10.40)
|
179 (14.32)
|
|
Heart disease
|
34 (1.87)
|
439 (2.41)
|
8 (1.04)
|
119 (1.55)
|
4 (3.20)
|
64 (5.12)
|
|
Cancer
|
50 (2.74)
|
558 (3.06)
|
15 (1.95)
|
223 (2.90)
|
5 (4.00)
|
50 (4.00)
|
|
Acute comorbiditiesc
|
||||||
|
Acute respiratory infection§
|
252 (13.83)
|
2,673 (14.68)
|
113 (14.69)
|
1,143 (14.86)
|
9 (7.20)
|
171 (13.68)
|
|
Pneumonia and influenza
|
18 (0.99)
|
169 (0.93)
|
11 (1.43)
|
70 (0.91)
|
1 (0.80)
|
14 (1.12)
|
|
Urinary tract infection*
|
99 (5.43)
|
683 (3.75)
|
36 (4.68)
|
284 (3.69)
|
8 (6.40)
|
41 (3.28)
|
|
Skin infection
|
164 (9.00)
|
1,566 (8.60)
|
68 (8.84)
|
652 (8.48)
|
5 (4.00)
|
96 (7.68)
|
|
Eye or Ear infection
|
4 (0.22)
|
33 (0.18)
|
3 (0.39)
|
15 (0.20)
|
0 (–)
|
0 (–)
|
|
Other infection*,†
|
149 (8.18)
|
1,256 (6.90)
|
69 (8.97)
|
533 (6.93)
|
5 (4.00)
|
73 (5.84)
|
|
Dyspepsia
|
35 (1.92)
|
282 (1.55)
|
11 (1.43)
|
120 (1.56)
|
2 (1.60)
|
23 (1.84)
|
|
Charlson Comorbidity Index at cohort entry
|
||||||
|
Low (0)
|
1,393 (76.45)
|
14,192 (77.93)
|
615 (79.97)
|
6,048 (78.65)
|
96 (76.80)
|
931 (74.48)
|
|
Medium (1–2)
|
405 (22.23)
|
3,822 (20.99)
|
147 (19.12)
|
1,574 (20.47)
|
26 (20.80)
|
296 (23.68)
|
|
High (>2)
|
24 (1.32)
|
197 (1.08)
|
7 (0.91)
|
68 (0.88)
|
3 (2.40)
|
23 (1.84)
|
Table 3
Comedications of MS cases and matched referent subjects at cohort entry, overall and stratified by type of MS
|
Characteristic
|
All MS cases
N = 1,822 [n (%)]
|
Referents
N = 18,211 [n (%)]
|
RRMSa cases
N = 769 [n (%)]
|
Referents
N = 7,690 [n (%)]
|
PPMS cases
N = 125 [n (%)]
|
Referents
N = 1,250 [n (%)]
|
|---|---|---|---|---|---|---|
|
Comedications (at cohort entry [index date] or within the 6 months before)
|
||||||
|
Systemic glucocorticoids*,†
|
180 (9.88)
|
713 (3.92)
|
69 (8.97)
|
288 (3.75)
|
8 (6.40)
|
52 (4.16)
|
|
Antidepressants*,†,§
|
380 (20.86)
|
1,582 (8.69)
|
132 (17.17)
|
662 (8.61)
|
28 (22.40)
|
102 (8.16)
|
|
Anticonvulsants*,†,§
|
122 (6.70)
|
225 (1.24)
|
40 (5.20)
|
88 (1.14)
|
11 (8.80)
|
25 (2.00)
|
|
Antidiabetics
|
24 (1.32)
|
283 (1.55)
|
12 (1.56)
|
112 (1.46)
|
0 (–)
|
30 (2.40)
|
|
Opioids*,†,§
|
345 (18.94)
|
1,585 (8.70)
|
122 (15.86)
|
621 (8.08)
|
23 (18.40)
|
133 (10.64)
|
|
NSAIDs*,†
|
316 (17.34)
|
1,806 (9.92)
|
122 (15.86)
|
710 (9.23)
|
21 (16.80)
|
152 (12.16)
|
|
Statins*
|
61 (3.35)
|
447 (2.45)
|
20 (2.60)
|
137 (1.78)
|
4 (3.20)
|
75 (6.00)
|
|
Antibiotics*,†
|
403 (22.12)
|
3,598 (19.76)
|
179 (23.28)
|
1,546 (20.10)
|
16 (12.80)
|
227 (18.16)
|
|
Muscle relaxants*,†,§
|
173 (9.50)
|
399 (2.19)
|
50 (6.50)
|
153 (1.99)
|
20 (16.00)
|
37 (2.96)
|
|
Antipsychotics*,†
|
122 (6.70)
|
387 (2.13)
|
54 (7.02)
|
160 (2.08)
|
5 (4.00)
|
20 (1.60)
|
|
Anti-Parkinson drugs*,†,§
|
23 (1.26)
|
54 (0.30)
|
8 (1.04)
|
17 (0.22)
|
3 (2.40)
|
4 (0.32)
|
|
PPIs*
|
83 (4.56)
|
657 (3.61)
|
24 (3.12)
|
243 (3.16)
|
6 (4.80)
|
68 (5.44)
|